Cytosorbents Achieves Operating Cash Flow Breakeven in Q3 2026 and Outlines DrugSorb-ATR Launch Plan
Cytosorbents Corporation (CTSO) announced a significant financial milestone during its Q3 2026 earnings call, reporting that the company achieved its objective of reaching operating cash flow breakeven in the third quarter. This achievement was noted excluding certain restructuring-related costs, signaling progress toward long-term fiscal stability. Looking ahead, the company outlined a strategic roadmap for its DrugSorb-ATR product, targeting an early 2027 De Novo regulatory pathway. Management estimates an initial market opportunity of $300 million across the United States and Canada, positioning the product as a key driver for future revenue growth.
